Sold Out
Book Categories |
Contributors, vii
Preface, xi
Section I Foundations for Understanding Antiviral Therapies in HCV
1 HCV Replication, 3
Michael R. Beard
2 Hepatitis C Virus Genotypes, 12
Scott A. Read and Mark W. Douglas
3 Immune Responses to HCV: Implications for Therapy, 17
David G. Bowen
4 Mechanisms of Action of Antiviral Drugs: The Interferons, 25
Edmund Tse and Michael R. Beard
5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs, 36
Fred Poordad and Grace M. Chee
6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors, 43
Lotte Coelmont, Leen Delang, Mathy Froeyen, Piet Herdewijn and Johan Neyts
7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors, 53
Laurent Chatel-Chaix, Martin Baril and Daniel Lamarre
8 Measuring Antiviral Responses, 60
Jean-Michel Pawlotsky and Stephane Chevaliez
Section II Efficacy and Clinical Use of Antiviral Therapies
9 Genotype 1: Standard Treatment, 67
Rebekah G. Gross and Ira M. Jacobson
10 Individually Tailored Treatment Strategies in Treatment-na¨ive Chronic Hepatitis C Genotype 1 Patients, 74
Johannes Wiegand and Thomas Berg
11 Genotype 1 Relapsers and Non-responders, 84
Salvatore Petta and Antonio Cra&xgrave;i
12 Standard Therapy for Genotypes 2/3, 90
Kenneth Yan and Amany Zekry
13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3, 97
Alessandra Mangia, Leonardo Mottola and Angelo Andriulli
14 Genotypes 2 and 3 Relapse and Non-response, 104
Stella Mart´inez, Jose Maria Sanchez-Tapias and Xavier Forns
15 Hepatitis C Genotype 4 Therapy: Progress and Challenges, 113
Sanaa M. Kamal
16 Antivirals in Acute Hepatitis C, 127
Heiner Wedemeyer
17 Antivirals in Cirrhosis and Portal Hypertension, 132
Diarmuid S. Manning and Nezam H. Afdhal
18 Treatment of Recurrent Hepatitis C Following Liver Transplantation, 140
Ed Gane
19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations, 150
Benjamin Terrier and Patrice Cacoub
20 Cytopenias: How they Limit Therapy and Potential Correction, 160
Mitchell L. Shiffman
21 The Problem of Insulin Resistance and its Effect on Therapy, 169
Venessa Pattullo and Jacob George
22 HIV and Hepatitis C Co-infection, 177
Gail V. Matthews and Gregory J. Dore
23 HCV and Racial Differences, 185
Andrew J. Muir
24 HCV and the Pediatric Population, 190
Kathleen B. Schwarz
25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV, 196
Alexander J. Thompson, John G. McHutchison and Geoffrey W. McCaughan
Index, 215
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish ListX
This item is in your CollectionAdvanced Therapy for Hepatitis C
X
This Item is in Your InventoryAdvanced Therapy for Hepatitis C
X
You must be logged in to review the productsX
X
X
Add Advanced Therapy for Hepatitis C, According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer. 3-4 million people each year are newly diagnosed carriers of the virus. Advance, Advanced Therapy for Hepatitis C to the inventory that you are selling on WonderClubX
X
Add Advanced Therapy for Hepatitis C, According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer. 3-4 million people each year are newly diagnosed carriers of the virus. Advance, Advanced Therapy for Hepatitis C to your collection on WonderClub |